Addressing Systemic Barriers for Sexual and Gender Minorities in Clinical Research Protocols

Clinical studies are a cornerstone for driving scientific advancement in the treatment of many diseases, including cancer. However, historical barriers continue to exist that exclude the LGBTQIA+ (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex and Asexual, and all other sexual and gender minorities) community, and especially transgender individuals, from clinical research programs.
At Johnson & Johnson Innovative Medicine, we are rethinking oncology clinical research protocols using inclusive language that reflects all eligible patients.